Danavorexton (TAK-925): an orexin receptor 2 agonist as a new 'arousal' agent.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38346840.
- Also identified by DOI 10.1016/j.bja.2023.12.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A preclinical study in animals has further characterised a new 'arousal' agent. Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation. Although danavorexton reverses opioid sedation, it does not compromise analgesia. This could be a useful addition to the postoperative drug cupboard.
Medical subject headings
- Analgesics, Opioid
- Arousal
- Piperidines
- Sulfonamides